Skip to Content
Global News Select

ObsEva Shares Buoyed After License Agreement With Organon

By Robb M. Stewart


ObsEva SA has agreed to licence the global development, manufacturing and commercial rights for an investigational agent being evaluated as a treatment for preterm labor to women's health company Organon & Co., buoying its shares early Tuesday.

In premarket trading, the biopharmaceutical company's stock was 34% higher after ending Monday at $2.52, up 21% since the end of last year. ObsEva was 1.7% lower after closing the previous session at $29.66.

Organon said it would license rights to ebopiprant, which if approved has the potential to be a first-in-class innovation for a common and serious condition with no approved therapies for acute treatment of preterm labor in the U.S.

Under the terms of their deal, Organon said ObsEva is entitled to receive tiered double-digit royalties on commercial sales as well as up to $500 million in upfront and milestone payments, including $25 million to be paid at signing, up to $90 million in development and regulatory milestones and up to $385 million sales based milestones.


Write to Robb M. Stewart at


(END) Dow Jones Newswires

July 27, 2021 07:13 ET (11:13 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.